Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...
End points were measured from baseline to week 52. Values are derived from an analysis of variance for the treatment policy estimand (top part of table) and a mixed-model-for-repeated-measures ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase ...
AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 monoclonal ...
Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...
Terns Pharmaceuticals announced significant updates regarding TERN-601, a novel oral GLP-1R agonist, following a successful Phase 1 clinical study and the completion of enrollment in its Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results